99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma

Cancer Immunology Immunotherapy

Volumn 42, Issue 5, 1996, Pages 291-296

  Vervoordeldonk, Susan F ^a,d   Heikens, Janneke ^b   Goedemans, Wim Th ^c   Merle, Pauline A ^a   Von Dem Borne, Albert E G Kr ^b   Van Royen, Eric A ^b   Slaper Cortenbach, Ineke C M ^a   Van Oers, Rien H J ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Mallinckrodt Medical BV   (Netherlands)

^d CENTRAL LABORATORY   (Netherlands)

Author keywords

B cell lymphoma; Radioimmunodetection; Technetium 99m

Indexed keywords

CD19 ANTIGEN; MONOCLONAL ANTIBODY; TECHNETIUM 99M; DIAGNOSTIC AGENT; TECHNETIUM;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; B CELL LYMPHOMA; IMMUNOLOGY; MOUSE; PILOT STUDY; RADIOIMMUNOASSAY; SCINTISCANNING;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MICE; PILOT PROJECTS; RADIOIMMUNODETECTION; TECHNETIUM;

EID: 0029665322     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050285     Document Type: Article

References (34)

1. Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff G, Goldenberg DM, Hor G (1994) Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 73: 896
2. Becker W, Behr Th, Rossler W, Wendler J, Kern P, Gramatzki M, Kalden JR, Goldenberg DM, Wolf F (1994) Ga-67-citrate versus Tc-99m-labelled LL2-Fab′-fragments (anti-CD22) in the staging of B cell non-Hodgkin's lymphoma (NHL) (abstract). J Immunother 16: 154
3. Behr TM, Becker WS, Bair HJ, Klein MW, Stuhler CM, Cidlinsky KP, Wittekind CW, Scheele JR, Wolf FG (1995) Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 36: 430
4. Bejcek BE, Wang D, Berven E, Pennell CA, Peiper SC, Poppema S, Uckun FM, Kersey JH (1995) Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res 55: 2346
5. Bianco JA, Sandmaier B, Brown PA, Badger C, Bernstein I, Eary J, Durack L, Schuening F, Storb R, Appelbaum F (1989) Specific marrow localization of an 131I-labeled anti-myeloid antibody in normal dogs: effects of a "cold" antibody pretreatment dose on marrow localization. Exp Hematol 17: 929
6. Blend MJ, Hyun H, Mills GQ, Buraggi G, Hughes L, Pinsky CM, Goldenberg DM (1994) Sensitivity of radioimmunodetection (RAID) using Tc-99m labeled monoclonal antibody fragment LL2 in B-cell lymphoma patients of different grades and stages (abstract). J Immunother 16: 153
7. Britton KE, Granowska M, Mather SJ (1991) Radiolabelled monoclonal antibodies in oncology. I. Technical aspects. Nucl Med Commun 12: 65
8. Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS (1992) Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res 52: 637
9. Carrasquillo J (1993) Imaging and dosimetry determinations using radiolabeled antibodies. In: Rosen, Steven T, Kuzel TM (eds) Immunoconjugate therapy of hematologic malignancies. Kluwer, London New York, p 65
10. Delaloye AB, Delaloye B (1994) Immunoscintigraphy in cancer care. Cancer 73: 900
11. DeNardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL (1990) Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res 50: 1014s
12. Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL, et al (1990) Imaging and treatment of B-cell lymphoma. J Nucl Med 31: 1257
13. Fazio F, Paganelli G (1993) Antibody-guided scintigraphy: targeting of the "magic bullet". Eur J Nucl Med 20: 1138
14. George AJ, Spooner RA, Epenetos AA (1994) Applications of monoclonal antibodies in clinical oncology. Immunol Today 15: 559
15. Goedemans WTh, Panek KJ, Ensing GJde Jong MThM (1990) A new, simple method for labelling of proteins with 99mTc by derivatization with 1-imino-4-mercaptobutyl groups: In: Nicolini M, Bandoli G, Mazzi U. Technetium and rhenium in chemistry and nuclear medicine. Cortina International, Verona, p 595
16. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO, et al (1991) Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9: 548
17. Hazra DK, Britton KE, Lahiri VL, Gupta AK, Khanna P, Saran S (1995) Immunotechnological trends in radioimmunotargeting. From "magic bullet" to "smart bomb". Nucl Med Commun 16: 66
18. Hekman A, Honselaar A, Vuist WMJ, Sein JJ, Rodenhuis S, Bokkel Huinink WW ten, Somers R, Rumke Ph, Melief CJM (1991) Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 32: 364
19. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, et al (1993) Radioimmunotherapy of B-cell lymphoma withanti-B1 (anti-CD20) antibody. N Engl J Med 329: 459
20. Kaplan WD, Southee AE, Annese ML, Jochelson MS, Nadler LM (1990) Evaluating low and intermediate grade non-Hodgkin's lymphoma (NHL) with gallium-67 (Ga) and Thallium-201 (T1) imaging (abstract). J Nucl Med 31: 793
21. Larson SM, Divgi CR, Scott AM (1994) Overview of clinical radioimmunodetection of human tumors. Cancer 73: 832
22. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72: 77
23. McLaughlin AF, Magee MA, Greenough R, Allman KC, Southee AE, Meikle SR, Hutton BF, Joshua DE, Bautovich GJ, Morris JG (1990) Current role of gallium scanning in the management of lymphoma. Eur J Nucl Med 16: 755
24. Moormeier JA, Williams SF, Colomb HM (1990) The staging of non-Hodgkin's lymphomas. Semin Oncol 17: 43
25. Murthy S, Sharkey RM, Goldenberg DM, Lee RE, Pinsky CM, Hansen HJ, Burger K, Swayne LC (1992) Lymphoma imaging with a new technetium-99m labelled antibody. LL2. Eur J Nucl Med 19: 394
26. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329: 1219
27. Reilly RM (1993) Immunoscintigraphy of tumours using 99Tcm-labelled monoclonal antibodies: a review. Nucl Med Commun 14: 347
28. Rie MA de, Zeijlemaker WP, Borne AEGKr von dem (1988) Inhibition by vinca alkaloids and colchicine, of antigenic modulation induced by anti-CD 19 monoclonal antibodies. Leukemia Res 12: 135
29. Serafini AN (1993) From monoclonal antibodies to peptides and molecular recognition units: an overview. J Nucl Med 34: 533
30. Stein R, Belisle E, Hansen HJ, Goldenberg DM (1993) Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother 37: 293
31. Uckun FM (1990) Regulation of human B-cell ontogeny. Blood 76: 1908
32. Vervoordeldonk SF, Merle PA, Leeuwen EF van, Borne AEGKr von dem, Slaper-Cortenbach ICM (1994) Preclinical studies with radiolabeled B cell McAbs for treatment of patients with B cell malignancies. Cancer 73: 1006
33. Vlasveld LT, Hekman A, Vyth Dreese FA, Melief CJ, Stein JJ, Voordouw AC, Dellemijn TA, Rankin EM (1995) Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother 40: 37
34. Waxman AD, Ramanna L, Eller D (1991) Characterization of lymphoma grade using thallium (Tl) and gallium (Ga) scintigraphy (abstract). J Nucl Med 32: 917